These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 17536074)

  • 1. Thiazolidinediones and heart failure: a teleo-analysis.
    Singh S; Loke YK; Furberg CD
    Diabetes Care; 2007 Aug; 30(8):2148-53. PubMed ID: 17536074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U; Pop-Busui R; Eagle KA
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Glitazones and congestive heart failure: update on PROactive, ADOPT, DREAM and RECORD clinical trials].
    De Flines J; Scheen AJ
    Rev Med Suisse; 2007 Aug; 3(122):1876, 1878-83. PubMed ID: 17896661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.
    Dahabreh IJ; Economopoulos K
    Clin Trials; 2008; 5(2):116-20. PubMed ID: 18375649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.
    Pinelli NR; Cha R; Brown MB; Jaber LA
    Ann Pharmacother; 2008 Nov; 42(11):1541-51. PubMed ID: 18957626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years.
    Grossman LD; Parlan G; Bailey AL; Yee G; Yu M; Chan JY
    Clin Ther; 2009 Jan; 31(1):74-88. PubMed ID: 19243708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The risk of myopathy associated with thiazolidinediones and statins in patients with type 2 diabetes: a nested case-control analysis.
    Koro CE; Sowell MO; Stender M; Qizilbash N
    Clin Ther; 2008 Mar; 30(3):535-42. PubMed ID: 18405791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study.
    Hartung DM; Touchette DR; Bultemeier NC; Haxby DG
    Pharmacotherapy; 2005 Oct; 25(10):1329-36. PubMed ID: 16185176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?
    Buckingham RE; Hanna A
    Diabetes Obes Metab; 2008 Apr; 10(4):312-28. PubMed ID: 18333890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis.
    Castagno D; Baird-Gunning J; Jhund PS; Biondi-Zoccai G; MacDonald MR; Petrie MC; Gaita F; McMurray JJ
    Am Heart J; 2011 Nov; 162(5):938-948.e2. PubMed ID: 22093212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials.
    Mannucci E; Monami M; Lamanna C; Gensini GF; Marchionni N
    Diabetes Obes Metab; 2008 Dec; 10(12):1221-38. PubMed ID: 18505403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of heart failure in patients with recent-onset type 2 diabetes: population-based cohort study.
    Leung AA; Eurich DT; Lamb DA; Majumdar SR; Johnson JA; Blackburn DF; McAlister FA
    J Card Fail; 2009 Mar; 15(2):152-7. PubMed ID: 19254675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Approach to the management of diabetic patients with heart failure: role of thiazolidinediones.
    Fonarow GC
    Am Heart J; 2004 Oct; 148(4):551-8. PubMed ID: 15459582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular risk of rosiglitazone: another perspective.
    Waksman JC
    J Pharm Pharmacol; 2008 Dec; 60(12):1573-82. PubMed ID: 19000361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical inquiries. Do TZDs increase the risk of heart failure for patients with diabetes?
    Baskin S; Neher JO; Dodson S; Hoffman R
    J Fam Pract; 2005 Aug; 54(8):723-4. PubMed ID: 16061064
    [No Abstract]   [Full Text] [Related]  

  • 16. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials.
    Hernandez AV; Usmani A; Rajamanickam A; Moheet A
    Am J Cardiovasc Drugs; 2011; 11(2):115-28. PubMed ID: 21294599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Saha SA; Molnar J; Arora RR
    Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Research profile. Is there a link? TZDs and congestive heart failure. Andrew Karter, PhD.
    Kordella T
    Diabetes Forecast; 2004 Jun; 57(6):98-100. PubMed ID: 15195634
    [No Abstract]   [Full Text] [Related]  

  • 19. Thiazolidinediones and the risk of edema: a meta-analysis.
    Berlie HD; Kalus JS; Jaber LA
    Diabetes Res Clin Pract; 2007 May; 76(2):279-89. PubMed ID: 17055103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14,237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone.
    Cobitz A; Zambanini A; Sowell M; Heise M; Louridas B; McMorn S; Semigran M; Koch G
    Pharmacoepidemiol Drug Saf; 2008 Aug; 17(8):769-81. PubMed ID: 18613278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.